Craniopharyngioma clinical trials at University of California Health
2 research studies open to eligible people
Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
open to eligible people ages 1-39
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
open to eligible people ages 18 years and up
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Irvine
Our lead scientists for Craniopharyngioma research studies include Sabine Mueller, MD, PhD, MAS Yoon Jae Choi.